GlassScriptPhysician profile
Jeffrey R Rehm
NPI 1548259823
$99,312.99
in general payments reported to CMS, 2019-2025
52 companies · $13K in 2025
The $13K reported for 2025 was more than what 94% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $49K · 2020: $8,799 · 2021: $14K · 2022: $4,376 · 2023: $4,317 · 2024: $5,207 · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K · Consulting Fee: $5,250 · Travel and Lodging: $1,749 · Education: $968.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,682.38 |
| Consulting Fee | $5,250.00 |
| Travel and Lodging | $1,749.24 |
| Education | $968.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $31,320.98 | 2019-2024 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21,410.66 | 2019-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Sunovion Pharmaceuticals INC. | $14,133.85 | 2019-2021 | |
| United Therapeutics Corporation | $7,653.31 | 2019-2025 | Tyvaso, Tyvaso, Remodulin |
| Astrazeneca Pharmaceuticals LP | $4,611.71 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Glaxosmithkline, LLC. | $4,353.52 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $1,352.48 | 2019-2025 | Dupixent |
| Actelion Pharmaceuticals US, INC. | $1,341.45 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Takeda Pharmaceuticals U.S.A., INC. | $1,186.79 | 2020-2025 | Glassia, Cuvitru |
| Genzyme Corporation | $1,126.04 | 2020-2025 | |
| Inspire Medical Systems, INC. | $1,046.44 | 2023-2025 | Inspire |
| Ani Pharmaceuticals, INC. | $1,043.98 | 2022-2025 | Purified Cortrophin Gel |
| Insmed, INC. | $918.84 | 2019-2025 | Arikayce, Brinsupri |
| Mallinckrodt Hospital Products INC. | $893.59 | 2020-2025 | Acthar |
| Bayer Healthcare Pharmaceuticals INC. | $765.50 | 2019-2025 |
Show all 52 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $593.17 | 2022-2025 | Tezspire |
| Harmony Biosciences LLC | $566.59 | 2020-2025 | Wakix |
| Pfizer INC. | $379.91 | 2019-2025 | |
| Jazz Pharmaceuticals INC. | $345.44 | 2019-2025 | |
| Grifols USA, LLC | $343.37 | 2022-2025 | Prolastin-C Liquid |
| Janssen Pharmaceuticals, INC | $342.34 | 2019-2023 | Xarelto |
| Shionogi INC | $331.66 | 2025 | Fetroja |
| Sanofi-Aventis U.S. LLC | $250.93 | 2022-2025 | |
| Paratek Pharmaceuticals, INC. | $240.97 | 2023-2024 | Nuzyra |
| Genentech USA, INC. | $212.31 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $203.95 | 2019-2023 | Zerbaxa, Recarbrio, Dificid |
| Pulmonx Corporation | $200.66 | 2024-2025 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Verona Pharma, INC. | $171.42 | 2025 | Ohtuvayre |
| Portola Pharmaceuticals, LLC | $164.40 | 2019 | |
| Electromed, INC. | $152.88 | 2019-2024 | Smartvest |
| E.R. Squibb & Sons, L.L.C. | $150.20 | 2019-2024 | Eliquis |
| Vifor Pharma, INC. | $149.72 | 2024-2025 | Zemaira |
| Astellas Pharma US INC | $143.11 | 2023-2024 | Cresemba |
| Lilly USA, LLC | $136.54 | 2025 | Zepbound |
| Mallinckrodt Enterprises LLC | $126.15 | 2019 | |
| Viatris Specialty LLC | $111.80 | 2025 | Yupelri |
| Philips North America LLC | $111.65 | 2019-2021 | |
| Axsome Therapeutics, INC. | $106.49 | 2024-2025 | Sunosi |
| Advanced Respiratory, INC | $93.93 | 2019-2021 | |
| Baxter Healthcare | $90.40 | 2022-2025 | Hillrom - Monarch Airway Clearance System |
| Gilead Sciences, INC. | $80.11 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $65.39 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $53.71 | 2022-2023 | Quviviq |
| Avadel Cns Pharmaceuticals, LLC | $43.32 | 2025 | Lumryz |
| Novo Nordisk INC | $43.28 | 2024-2025 | Wegovy |
| Teva Pharmaceuticals USA, INC. | $41.19 | 2019-2021 | |
| Vanda Pharmaceuticals INC. | $32.13 | 2023 | Hetlioz |
| Alexion Pharmaceuticals, INC. | $20.26 | 2021 | |
| Nabriva Therapeutics, Plc | $16.25 | 2020 | |
| Circassia INC. | $15.44 | 2019 | |
| Shire North American Group INC | $12.27 | 2019 | |
| Itamar Medical INC | $10.51 | 2025 | Watchpatone |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Rehm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.